Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke
Launched by REHA RHEINFELDEN · Dec 12, 2007
Trial Information
Current as of May 02, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients after first-ever ischemic stroke with a clinical relevant paresis of the upper and lower limb (general clinical muscle testing below level four)
- • correlation of clinical symptoms with a brain imaging (CT or MRI)
- • able to communicate with the neurological examiner and understand the aim/matter of the study (with or without aphasia)
- • start of the first oral application of the study drug between the fourteenth and 60th day after stroke onset
- • older than 13 years
- • given written informed consent (or two independent witnesses)
- Exclusion Criteria:
- • intracranial or (chronic) subdural hemorrhages
- • any additional neurological or psychiatric illnesses
- • instable arrythmia
- • not controlled or treated arterial hypertension
- • ensured cardioembolic event
- • anxiolytica, neuroleptica, or alpha-adrenergic antagonists or agonists respectively
- • certain anticonvulsiva or antihypertonica
- • manifest hyperthyreosis
- • dementia or terminal illnesses
- • epilepsy, phaeochromocytoma or glaucoma
- • women known to be pregnant or lactating
About Reha Rheinfelden
Reha Rheinfelden is a leading clinical trial sponsor dedicated to advancing rehabilitation and therapeutic innovations through rigorous research and development. With a focus on enhancing patient outcomes, Reha Rheinfelden collaborates with healthcare professionals and academic institutions to conduct high-quality clinical trials. The organization is committed to adhering to ethical standards and regulatory guidelines, ensuring the safety and efficacy of new treatments. By fostering a multidisciplinary approach, Reha Rheinfelden aims to contribute significantly to the fields of rehabilitation and recovery, ultimately improving the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rheinfelden, Ag, Switzerland
Patients applied
Trial Officials
Thierry M. Ettlin, Prof.
Principal Investigator
Reha Rheinfelden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials